The Favorable Effects of a High-Intensity Resistance Training on Sarcopenia in Older Community-Dwelling Men with Osteosarcopenia: The Randomized Controlled FrOST Study

This article was published in the following Dove Press journal:
Clinical Interventions in Aging

Theresa Lichtenberg¹
Simon von Stengel¹
Cornel Sieber²
Wolfgang Kemmler¹

¹Osteoporosis Research-Center, Institute of Medical Physics, Faculty of Medicine, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany;
²Internal Medicine and Geriatric Medicine, Institute of Biomedicine of Aging, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany

Purpose: Sarcopenia, the loss of muscle mass combined with the loss of muscle function, has become a public health issue. There is an urgent need for interventions. The study aimed to determine the effect of high-intensity resistance training (HI-RT), a time- and cost-efficient training modality, on sarcopenia in osteosarcopenic (OS) older men.

Methods: Forty-three community-dwelling men aged ≥ 72 years from Northern Bavaria, Germany, with OS were randomly assigned to either an active HI-RT group (HI-RT) or an inactive control group (CG). Both received dietary protein (up to 1.5 g/kg/day in HI-RT and 1.2 g/kg/day in CG) and Vitamin-D (up to 800 IE/d) supplements. The HI-RT was applied as a consistently supervised single-set training on resistance exercise machines using intensifying strategies, with two training sessions/week, structured into three phases (ranging from 8 to 12 weeks) totaling 28 weeks. The primary study endpoint was the Sarcopenia Z-score; secondary endpoints were changes in the underlying physiological parameters, skeletal muscle mass index (SMI), handgrip-strength and gait velocity.

Results: The results show a significant effect of the exercise intervention on the sarcopenia Z-score in the HI-RT ($p < 0.001$) and a significant worsening of it in the CG ($p = 0.012$) in the intention-to-treat analysis, as well as a significant intergroup change ($p < 0.001$). Analysis upon the underlying parameters showed a significant increase of skeletal muscle mass index (SMI) in the HI-RT group ($p < 0.001$) and a significant intergroup difference of SMI ($p < 0.001$) and handgrip strength ($p < 0.001$). There were no adverse effects related to dietary supplementation or training.

Conclusion: The results clearly confirm the favorable effects of HI-RT on sarcopenia. We conclude that HI-RT is a feasible, highly efficient and safe training modality for combating sarcopenia, also in the elderly.

Keywords: HI-RT, high-intensity resistance training, osteosarcopenia, sarcopenia, SMI, community-dwelling, older people

Correspondence: Wolfgang Kemmler;
Theresa Lichtenberg
Institute of Medical Physics, Faculty of Medicine, Friedrich-Alexander University of Erlangen-Nürnberg, Henkestrasse 91, 91052, Erlangen, Germany
Tel +49 9131 8523999
Fax +49 9131 8522824
Email wolfgang.kemmler@imp.uni-erlangen.de;
theresa.lichtenberg@gmail.com

Introduction

Sarcopenia – the degeneration of muscle mass combined with loss of muscle function due to aging¹ has become a public health matter.² The multiple adverse health outcomes associated with low muscle mass (fractures and falls,^{3–7} insulin resistance and the risk of prediabetes,^{8,9} cardiovascular diseases,¹⁰ cognitive impairment,¹¹ depression¹² and others¹³), the impact of sarcopenia on the individual's life (loss of independence,¹⁴

reduced quality of life,^{12,15,16} earlier necessary admission to nursing homes^{14,17}) and the resulting socioeconomic burden^{18–20} have made the necessity for interventions clear. Many studies have already proven the positive effects of resistance training (RT) combined with a protein-rich diet on sarcopenia.^{21–26} A standardized treatment approach that can be applied to a wide range of sarcopenic patients and includes a validated training protocol has yet to be defined. The training should be time-efficient, considering reasons for abstaining from recommended exercise doses have been time restriction and little enthusiasm^{27,28} and cost-efficient in the face of the high and growing prevalence of sarcopenia²⁹ and the resulting financial burden for stakeholders.^{18,19,30–32} A training modality meeting these criteria is high-intensity resistance training (HI-RT), a single-set resistance training at an intensity of load at 70–85% of the one-repetition maximum (1RM).³³ To have a maximum effect on muscle strength and mass and also parameters like bone density^{34,35} and hormonal levels,³⁶ relative intensity of 70% RM and up is needed, which falls in the range of HI-RT.

A protocol using a modern high-intensity method has not been applied to the often fragile³⁰ cohort of sarcopenic patients. It is time to challenge the presumptions of HI-RT being too demanding and risky for the elderly and make use of this efficient training modality for sarcopenic patients. This study is the first to assess HI-RT as a favorable therapy option for osteosarcopenic community-dwelling men, with this publication focusing on sarcopenia, while the aspect of osteopenia will be dealt with in another publication.

Our central hypothesis was that HI-RT combined with supplemental protein has a significant effect on Sarcopenia, ie, the Sarcopenia Z-score, compared to the control group (CG), which only received protein supplementation.

Our secondary hypothesis was that skeletal muscle mass index (SMI), as an underlying physiologic parameter of the Sarcopenia Z-score, significantly increases in the HI-RT group compared to the CG.

Methods

Trial Design

The Franconian Osteopenia and Sarcopenia Trial (FrOST) is an 18-month randomized controlled exercise study with a balanced parallel two-group design. The research focusses on a cohort of community-dwelling men 72 years and older with morphological sarcopenia and osteopenia. FrOST predominantly pursues two main aims. (1) To determine the effect of HI-RT on bone parameters related to osteoporosis;

(2) to evaluate the impact of HI-RT on muscular parameters related to Sarcopenia. The present publication reports changes in sarcopenia criteria from within the first 6 months of the intervention (June–December 2018). The Institute of Medical Physics (IMP), University of Erlangen-Nürnberg (FAU), Germany, planned, initiated and realized the project, which was approved by the University Ethics Committee of the FAU (Ethikantrag 67_15b and 4464b). The study complies with the Helsinki Declaration “Ethical Principles for Medical Research Involving Human Subjects.” After receiving detailed information, all study participants gave their written informed consent. The project was registered under ClinicalTrials.gov: NCT03453463.

Participants

Participant recruitment of the FrOST was a multi-stage process. We based FrOST on the Franconian Sarcopenic Obesity (FranSO) study,³⁷ an epidemiologic study with 965 community-dwelling men 70 years+, conducted in 2016. Precisely 24 months later, in January/February 2018, participants from the lowest quartile for SMI (n=242) were invited for a 2-year follow-up (2-year FU) assessment. Out of them, 177 men 72 + were willing to participate and remained after applying the following inclusion criteria: a) Community-dwelling status; b) no amputations of limbs or cardiac pacemaker implants during the last 2 years; c) no (new) implementation of glucocorticoid therapy >7.5 mg/d during the previous 2 years; d) no cognitive impairment that could confound the assessments³⁸ and e) no alcohol abuse of more than 60 g/d ethanol. These 177 remaining men then got reevaluated (2-year FU): only participants with an SMI <7.50 kg/m² (n=103) as determined by direct-segmental, multi-frequency Bio-Impedance-Analysis (DSM-BIA) were further invited for body composition and bone mineral density analysis using Dual-Energy X-ray Absorptiometry (DXA). Subjects were finally included in FrOST when

a) SMI, as assessed by DXA, was below 7.26 kg/m² (≤ -2 standard deviations (SD) T-Score, ie, sarcopenia^{1,39}),

b) bone mineral density at the region of interest (ROI), ie, either the lumbar spine or the proximal femur (total hip or femoral neck) was ≤ -1 SD T-Score (ie, osteopenia⁴⁰),

c) there was no secondary osteoporosis or history of hip fracture and subjects would be able to visit our lab or the gym. Finally, 43 men were eligible and willing to participate in the study. Correspondingly, these 43 subjects were randomly assigned either to a HI-RT (n=21) or an inactive CG (n=22). Figure 1 shows the participants' flow through the study.

Randomization Procedures

Stratified for SMI (3 strata), the 43 study participants were randomly and equally assigned to two study arms, a) HI-RT (n=21) or b) CG (n=22). By drawing lots, participants allocated themselves to the study group. Lots were placed in opaque plastic shells (“kinder egg,” Ferrero, Italy) and drawn from a bowl. Neither participants nor researchers knew the allocation

beforehand. Subsequently, the primary investigator Wolfgang Kemmler (WK) enrolled participants and instructed them in detail about their status, including corresponding dos and don’ts.

Blinding

We conducted a blinded approach that focused on outcome assessors and test assistants only. Outcome assessors were

Figure 1 Participants' flow through the study.

Abbreviations: DSM-BIA, direct-segmental multi-frequency bioimpedance analysis; DXA, dual-energy X-ray absorptiometry; HI-RT, high-intensity resistance training; CG, control group; FU, follow-up; ITT, intention to treat.

unaware of the participant's group status (HI-RT or CG) and were not allowed to ask correspondingly.

Study Procedure and Intervention

Subjects have been intensively informed about dos and don'ts by the principal study investigator (WK). Maintaining and not changing physical activity and exercise outside the study intervention as well as maintaining dietary habits has been requested of them. Furthermore, all participants have been asked to restrain from intense physical activity and exercise 48 h pre-assessment.

Exercise Protocol

The consistently supervised resistance exercise training started in June 2018 and has been performed in a well-equipped gym (Kieser-Training, Erlangen, Germany), which is centrally located and can be easily reached via public transportation.

Participants of the HI-RT group have been provided with training logs, which prescribe exercises, number of sets (first phase only), number of repetitions (reps), movement velocity and the required exercise intensity (non-repetition maximum (nRM), repetition maximum (RM) or work to failure (MF))⁴¹ in the given training phase.

The following example is intended to help the reader better understand the concept of intensity in resistance training and how modification of repetition maximum and load regulate intensity.

An athlete who can lift 100 kg in the bench press in the correct form once has a 1RM of 100 kg for that specific exercise, thus lifting 75–80 kg would fall into the range of 75–80%RM, defined as the intensity of load.⁴² Work to failure refers to the intensity of effort and means respective athlete can lift x repetitions until muscle failure (MF), ie, the “set endpoint when trainees complete the final repetition possible whereby if the next repetition was attempted they would definitely achieve MF” as defined by Giessing et al.⁴³ In practice, the work to failure approach is usually achieved with a self-determined repetition maximum (sdRM), meaning the “set endpoint when the trainee determines they could not complete the next repetition if it were attempted (ie, they predict MF on the following repetition) as Steele et al⁴¹ have extended the four definitions by Giessing et al.⁴³

We did not prescribe a precise number of reps or a given load as deduced by 1RM assessments or 1RM calculated by xRM-tests (eg, Ref. 44). Instead, we prescribed the range of reps and the corresponding level of effort (nRM, RM) to regulate exercise intensity.

Consequently, the participants had to choose a weight for themselves with which they could perform an exercise x - y times (= prescribed range of reps) in order to reach the predefined intensity of effort (= prescribed level of effort)

During the first 28 weeks of the intervention, the resistance training (RT) was structured into three phases with 2 training sessions/week. (Either on Monday or/and Wednesday or/and Friday morning.) During phase 1, we started with 4 weeks of briefing and familiarization, and a further 8 weeks of conditioning. Strong emphasis was put on bringing the importance of the proper relationship between repetitions and corresponding load across to the patients under the premise of the prescribed repetition maximum.⁴¹ Per session, 12 out of 14 exercises (latissimus front pulleys, rowing, back extension, inverse fly, bench press, shoulder press, lateral raises, butterfly with extended arms, crunches, leg press, leg extension, leg curls, leg adduction and abduction) were conducted over the full range of motion on resistance-devices (MedX, Ocala, FL, USA). The protocol prescribed 1–2 sets of 8–15 reps, time under tension of 2s concentric, 1s isometric and 2s eccentric (2s-1s-2s) per rep and a non-repetition maximum (nRM: maximum effort minus 1–3 reps).⁴¹ Breaks between sets or exercises were consistently 90–120 s. Applying these criteria to the example earlier, the bodybuilder would first have to determine which weight he can lift on the bench press 15 times with correct form before MF and then deduct 1–3 reps, thus lifting this determined weight for 12–14 reps in order to reach the non-repetition maximum.⁴¹

During phase 2, the single-set approach, characteristic for HI-RT, was implemented. Up from this phase, we applied 8-week phases, each consisting of 2 linearly periodized four 4-week phases, with each fourth week as a recovery week with low exercise intensity. Fourteen to fifteen exercises out of a pool of 18 (additionally to the above-listed exercises, calf raises, hip extension, pullovers, lateral crunches) were applied. Apart from the 10 core exercises consistently used, weekly sessions slightly differed for the exercises prescribed. Apart from the recovery weeks with no prescription of nRM, the protocol prescribed 7–18 reps/set, selecting a load that ensured maximum effort (RM) –1 rep (up to 10 reps) to –2 reps (more than 10 reps). Of importance, we did not prescribe a target repetition (eg, 7 reps). Instead, we specified a repetition sector (7–10 reps) that should be realized by the participants keeping in mind the level of effort (nRM, RM). Breaks between the exercises were consistently 90 s. We generated periodization by decreasing the number of reps from 15–18 reps/set/session to 7–10 reps/set/session during the 3-week cycle of linear

periodization. We placed strong emphasis during phase 2 on movement velocity that varied between 4s-1s-4s to 1s-1s-2s per rep. However, we did still not focus on an explosive movement during the concentric phase during phase 2. Coming back to the exemplary bodybuilder, during phase 2, he would start with a weight in the bench press, which he would be able to perform 20 reps with and then deduct 2 reps from it to determine the nRM. Over 3 weeks, he would decrease the number of repetitions down to 7–10 reps still ensuring to reach the nRM by choosing correspondingly higher loads.

Using a comparable training schedule described for phase 2; however, with a slightly lower range of repetitions (12–15 decreasing to 6–8 reps), the repetition maximum approach⁴¹ characteristic for HI-RT was introduced during phase 3. We carefully increased the number of (core) exercises that should be executed almost to muscular failure (here: defined as 1RM⁴¹) from four during week 1 to eight in week 7 (week 8 was a recovery week). Figure 2 visualizes the exercise protocol.

Protein Supplementation

Protein supplementation has been based on 4-day dietary protocols (see below). We have intended a total protein intake of 1.5 g/kg body mass/d in the HI-RT and a corresponding intake of 1.2 g/kg body mass/d²⁵ in the CG. Participants with a dietary protein intake <1.5 g/kg/d (HI-RT) or <1.2 g/kg/d (CG) have been provided with protein supplements. The protein powder used in FrOST (Active PRO80, inkospor, Roth, Germany) consists of whey protein with a chemical score of 156. One hundred grams contain 80 g of protein (10.4 g of Leucine), 5 g of carbohydrates and 1.8 g of fat resulting in

a calorific value of 362 kcal/100 g protein powder. Furthermore, 300 mg of calcium has been enclosed with a 25 g/portion of the protein powder. Participants have been requested to ingest the prescribed dose accurately on a daily base and to split doses higher than 30 g/d. We have suggested to mix the protein powder with low-fat milk when applicable (or possible) in order to increase the participants' dietary calcium intake. Compliance with prescribed protein powder intake has been queried regularly during the exercise sessions.

Vit-D/Calcium Supplementation

Based on blood concentrations of 25 OH Vitamin-D 3 (25-OH D3), participants with levels below 30 ng/mL (n=37) have been asked to supplement 10.000 IE/week (2x2500 IE/d, twice a week; MYVITAMINS, Manchester, UK). Participants between 30 and 40 ng/mL (n=4) have been requested to take 5.000 IE/week (2x2500 IE/d, once a week).

We have intended to realize a calcium intake of about 1000 mg/d in all participants.⁴⁵ Based on a dietary calcium questionnaire (Rheumaleague Suisse), we calculated the amount of daily dietary calcium intake. After also considering the calcium provided by the protein powder, we prescribed the additionally required daily calcium to be ingested by calcium capsules (Sankt Bernhard, Bad Dietzenbach, Germany). Each capsule contains 625 mg of calcium-carbonate with 250 mg of pure calcium.

Study Outcomes

Primary Outcome

Changes in Sarcopenia Z-score applying the European Working Group of Sarcopenia in Older People (EWGSOP I) approach¹ from baseline to six-month FU.

Figure 2 Exercise protocol.

Abbreviations: reps, repetitions; con, concentric; iso, isometric; ecc, eccentric; nRM, non-repetition maximum; RM, one-repetition maximum.

Secondary Outcomes

Changes in Sarcopenia criteria constituting the Sarcopenia Z-score from baseline to six-month FU, ie,

- Changes in SMI
- Changes in habitual gait velocity
- Changes in handgrip strength

Changes to Trial Outcomes After Trial Commencement

No changes to trial outcomes were conducted after trial commencement.

Assessments

Baseline and FU assessments were performed using the identical calibrated devices, in precisely the same setting and at the same time of the day (± 90 mins). However, research assistants who guided and supervised the tests were not consistently identical between baseline and 6-month FU.

The Sarcopenia Z-score, according to the EWGSOP-I approach, included SMI, gait velocity and handgrip strength. Cut-off values applied were 0.8 m/s for gait velocity and 30 kg for handgrip strength. However, divergent from the cut-off value for skeletal muscle mass index (SMI) suggested by the EWGSOP-I for BIA assessments,^{46–48} we applied the “Weissenfels Score” (7.177 kg/m^2),^b (T-Score-based approach of SMI ($\text{ASMM}/\text{height}^2$) based on 2 SD below the mean value of a young reference cohort of 1189 healthy Caucasian men 18–35 years old.) specifically designed for this northern Bavarian cohort of CD men 70 years+.⁴⁹ Based on the cut-offs and individual data, we calculated the Sarcopenia Z-score:

$$\text{Z-Score} = ((30 - \text{individual handgrip strength})/\text{SD handgrip strength}) + ((0.8 - \text{individual gait velocity})/\text{SD gait velocity}) + ((7.177 - \text{individual SMI})/\text{SD SMI}).$$

Height was measured using a stadiometer (Holtain, Crymych Dyfed., Great Britain), body mass and composition were determined via direct-segmental multi-frequency bioimpedance analysis (DSM-BIA; InBody 770, Seoul, Korea) and by DXA (QDR 4500a, Discovery-upgrade, Hologic Inc., Bedford, USA). In both cases, we applied standard protocols suggested by the manufacturer. Since we opt to focus on BIA assessment of muscle mass during the 6-month FU assessment, we would like to report methods of DXA evaluation of bone mineral density and body composition in a future publication.

Soft lean body mass was defined as bone and fat-free body mass. Body fat (%) refers to the amount of fat in the

whole body. Comparable to the calculation of the BMI (ie, $\text{body mass}/\text{height}^2$; kg/m^2) and following the approach suggested by Baumgartner et al,⁵⁰ skeletal muscle mass index (SMI) was calculated as fat-free mass of the upper and lower extremities (=appendicular skeletal muscle mass) divided by squared body height (kg/m^2). In order to standardize the BIA assessment, we consistently used the same BIA test protocol, which includes minor physical activity for 8 hrs and 15 mins of rest in a supine position immediately before the BIA assessment. Furthermore, all participants were provided with written specifications about dos and don'ts, including essential nutritional guidance 24 before testing.

A standardized assessment of habitual gait speed⁵¹ was performed using the 10 m protocol recommended for research.⁵² Participants started walking in an upright position 3 m before the first photosensor (HL 2–31, TagHeuer, La Chaux-de-Fonds, Suisse) and stopped 2 m after the second photosensor. Tests were performed wearing regular shoes without any specific walking aids. Standardized instructions to the participants were consistently “walk at a speed just as if you were walking along the street to go to the shops.”

Handgrip strength was tested three times each for the dominant and the non-dominant hand using a calibrated Jamar handgrip dynamometer (Sammons Preston Inc., Bollington, USA). Handgrip width was adjusted individually to participant hand size. Tests were performed while standing upright, arms down by the side⁵³ with 30 s rest between the trials. The standardized instruction to the participants was consistently “squeeze as strongly as possible.” We included the highest result of the three trials for the dominant hand in the analysis.

General characteristics (eg, family and educational status, professional career), medication, diseases and lifestyle (including physical activity and exercise⁵⁴), falls, injurious falls, fractures and self-rated degree of independence were determined using a standardized questionnaire completed by the participants while visiting our lab. Before the tests, we asked participants to list their medications and diseases in order to generate completeness and accuracy of the questionnaire. This summary was checked by the principal investigator (WK) in cooperation with the participants before the tests were conducted. During this interaction, the degree of independence and autonomy, family status, social network and use of ambulatory nursing services was inquired more specifically. The 6-month FU questionnaire predominately focused on changes in confounding variables concerning lifestyle, including physical activity and

exercise, diseases, medication and dietary intake. Further, we asked for falls and self-rated degree of independence.

Sample Size

Sample size analysis of FrOST was based on quantitative computed tomography (QCT) of the lumbar spine. However, since this or other bone parameters were not determined at 6-month FU, we would like to report the statistical power of our sample size (HI-RT: $n=21$ vs CG: $n=22$) with the focus on the Sarcopenia Z-score. Applying a *t*-test based sample size calculation to the effect (exercise vs CG) on Sarcopenia Z-score (0.46 ± 0.51) reported by a comparable trial with older men,³⁷ the sample size of 21 participants/group corresponds to a 86% power ($1-\beta$) at a type-I-error of $\alpha=0.05$.

Statistical Analysis

The intention to treat (ITT) analysis included all participants who were randomly assigned to the two study arms (HI-RT vs CG) regardless of their compliance or whether they were lost to FU. R statistics software (R Development Core Team Vienna, Austria) was used in combination with multiple imputation by Amelia II.⁵⁵ The full data set was used for multiple imputations, with imputation being repeated 100 times. Overimputation diagnostic plots provided by Amelia II confirmed that the multiple imputation worked well in all cases. Based on a statistically and graphically checked normal distribution, the primary and secondary outcomes that are addressed here were analyzed by dependent *t*-tests for within-group (intra-group) changes. Pairwise *t*-test comparisons (HI-RT vs CG) with pooled SD were applied in order to identify group differences. Mean values (MV), standard deviations (SD) and 95% confidence intervals (95% CI) were used to describe the data. Additionally, we applied a per-protocol analysis (PPA) for the primary study endpoint that included only participants with complete data sets. To identify differences between the groups, we used repeated-measures ANOVA in the PPA. All tests were two-tailed; significance was accepted at $p < 0.05$. We further calculate Standardized Mean Difference (SMD) according to Cohen (d ;⁵⁶) to analyze effect sizes.

Results

One participant of the CG and two participants of the HI-RT group got lost to FU. Concerning the latter group, one man withdrew immediately after randomization (did not agree with the group assignment), another participant was unable to visit the 6-month FU due to therapy of prostate

cancer. One man of the CG was unable to visit the 6-month FU due to influenza infection. Attendance to the HI-RT sessions was high.

In summary, subjects participated in $95 \pm 4\%$ of the 52 sessions. The average exercise time/session after the conditioning period was 50 ± 9 mins. Apart from periods of muscle pain and delayed onset of muscular soreness (DOMS), no further exercise-induced complaints or unintended side effects were reported. Table 1 gives baseline characteristics. Apart from body height, no significant differences between the groups were observed.

Tables 2–4 report changes from baseline to 6-month FU assessment: Tables 2 and 3 in primary and secondary endpoints and Table 4 in potentially confounding parameters. Asterisks indicate the significance levels of intragroup changes. Differences in absolute changes between the groups are reported using mean difference and 95% confidence intervals (95% CI). Finally, in the right row of the table, exact *p*-values are listed for baseline differences and differences in absolute change in the given parameter between the CG and HI-RT. Additional listings in the text complete this data; absolute *p*-values for intragroup changes, SMD for group differences in absolute

Table 1 Baseline Characteristics of the Participants of the CG and HI-RT Group

Variable	CG ($n=22$)	HI-RT ($n=21$)	<i>p</i>
Age [years]	79.2 ± 4.7	77.8 ± 3.6	0.262
Body height [cm]	169.2 ± 5.5	172.8 ± 5.2	0.039
Body mass [kg] ^a	70.2 ± 7.1	74.7 ± 10.1	0.113
Soft lean body mass [kg] ^a	46.9 ± 3.4	48.4 ± 3.3	0.164
Total body fat rate [%]	28.6 ± 5.8	30.5 ± 6.8	0.330
Number of diseases [n] ^b	2.14 ± 0.92	2.00 ± 1.11	0.656
Hip or knee arthrosis [n]	2	2	0.959
Chronic low back pain [n]	4	3	0.731
Physical activity [Index] ^c	4.15 ± 1.53	4.45 ± 1.32	0.490
Exercisers [n]	13	11	0.654
Training volume [min/week]	59 ± 56	46 ± 52	0.780
25 OHD baseline [ng/mL]	21.6 ± 8.4	17.5 ± 7.0	0.126
Energy intake [kcal/d] ^d	2291 ± 590	2155 ± 416	0.407
Protein intake [g/d] ^d	89.3 ± 25.9	81.6 ± 19.9	0.299
Independence grade [Index] ^e	1.68 ± 0.82	1.80 ± 0.80	0.791
Smokers [n]	4	3	0.959

Notes: ^aAs determined by DSM-BIA (InBody 770, Seoul, Korea). ^bUsing the ICD-10-based disease cluster of Schäfer et al.⁵⁷ ^cScale from (1) very low to (7) very high.⁵⁴ ^dAs determined by a 4-day dietary record. ^eRating scale from 1 (no help from others to conduct my daily life at all) to 7 (unable to conduct most challenges of daily life).

Abbreviations: DSM-BIA, direct-segmental multi-frequency bioimpedance analysis; HI-RT, high-intensity resistance training; CG, control group.

Table 2 Baseline Data and Changes in the Sarcopenia Z-Score in the GC and HI-RT and Corresponding Between-Group Differences

	CG MV±SD	HI-RT MV ±SD	Difference MV (95% CI)	p-Value
Sarcopenia Z-score [Index]				
Baseline	-0.11 ± 1.18	-0.09 ± 1.94	–	0.981
Six-month follow-up	0.43 ± 0.74*	-1.01 ± 0.78***	1.44 (0.95 to 1.92)	<0.001

Notes: *P<0.05; ***P<0.001.

Abbreviations: HI-RT, high-intensity resistance training; CG, control group; MV, mean value; SD, standard deviation; CI, confidence interval.

Table 3 Baseline Data and Changes in the Sarcopenia Criteria in the Control Group (CG) and High-Intensity Resistance Training Group (HI-RT) and Corresponding Between-Group Differences

	CG MV ± SD	HI-RT MV ± SD	Difference MV (95% CI)	p-Value
Skeletal Muscle Mass Index (SMI) [kg/m ²]				
Baseline	7.10 ± 0.30	7.07 ± 0.33	–	0.681
Changes	-0.03 ± 0.21	0.30 ± 0.22***	0.33 (0.19 to 0.46)	<0.001
Habitual gait velocity [m/s]				
Baseline	1.26 ± 0.15	1.25 ± 0.17	–	0.803
Changes	-0.004 ± 0.051	0.016 ± 0.055	0.020 (-0.01 to 0.06)	0.091
Handgrip strength [kg]				
Baseline	30.0 ± 4.3	30.7 ± 5.1	–	0.675
Changes	-2.04 ± 2.13***	0.15 ± 2.26	2.19 (0.78 to 3.06)	<0.001

Notes: ***P<0.001.

Abbreviations: HI-RT, high-intensity resistance training; CG, control group; MV, mean value; SD, standard deviation; CI, confidence interval.

Table 4 Changes in Potentially Confounding Parameters in the CG and HI-RT and Corresponding Between-Group Differences

	CG MV±SD	HI-RT MV±SD	Difference MV (95% CI)	p-Value
Dietary energy uptake [kcal]				
Changes	7.8 ± 135	13±166	5 (-93 to 104)	0.971
Dietary Protein uptake [g/d]				
Changes	-2.1 ± 12.9	3.5 ± 16.4	5.6 (-4.0 to 15.3)	0.251
Physical activity [Index] ^a				
Changes	0.20 ± 0.88	0.22 ± 0.91	0.02 (-0.58 to 0.63)	0.941

Notes: ^aBased on a scale from (1) very low to (7) very high; see Table 1.

Abbreviations: HI-RT, high-intensity resistance training; CG, control group; MV, mean value; SD, standard deviation; CI, confidence interval.

change and percentage changes from baseline to follow-up are mentioned where applicable and meaningful.

Changes in the primary study endpoint are in Table 2. Based on widely identical baseline data, the Sarcopenia Z-score significantly (p<0.001) improved in the HI-RT and significantly worsened in the CG (p=0.012). Differences between the groups concerning Sarcopenia-Z-score changes

are significant (p<0.001; SMD 1.89). The additionally performed per-protocol analysis using repeated measures ANOVA confirms this result with a slightly lower effect size (p<0.001; SMD 1.77).

Addressing the underlying criteria of the Sarcopenia Z-score according to EWGSOP-I,¹ ie, SMI, habitual gait velocity and handgrip strength, we observed significant

increases for SMI in the HI-RT (+4.2%, $p < 0.001$) and slight decreases in the CG (−0.4%, $p = 0.548$). The difference between the groups was significant ($p < 0.001$, SMD: 1.53) (Table 3). Habitual gait velocity did not change in the CG (−0.3%, $p = 0.639$) and slightly increased in the HI-RT (+1.3%, $p = 0.061$). The difference between the groups was not significant ($p = 0.091$, SMD: 0.38) (Table 3). Handgrip strength maintained in the HI-RT (+0.5%, $p = 0.89$) and significantly decreased in CG (−6.8%, $p < 0.001$). Differences between the groups were significant ($p < 0.001$, SMD: 1.00).

Table 4 gives changes in parameters with a potential impact on our results. There were no relevant changes in diet or lifestyle and participants did not report changes in habitual exercise habits. Apart from the participants that were lost to follow-up (prostate cancer), no participant listed relevant changes in medication, diseases, musculoskeletal injuries or cardiometabolic events. Extended periods (≥ 2 weeks) of diseases or inactivity were also not recorded.

Discussion

The presented results clearly confirm our primary hypothesis – HI-RT combined with supplemental protein (HI-RT&P) had a significantly favorable effect on Sarcopenia, ie, the decrease of the Sarcopenia Z-score, compared to the CG, which only received protein supplement.

This result indicates that without exercise stimuli, sarcopenia naturally progresses and worsens and that the amount of supplemented protein in the CG (1.2 g/kg/d²⁵) alone was ineffective in maintaining muscle mass and function. We had at least expected maintenance of muscle strength and muscle mass because of the benefits of protein supplementation reported on in several publications^{25,26} and the positive results of the FranSO study by Kemmler et al,³⁷ which formed the basis of FrOST. FranSO indicated a sole effect of protein supplementation, even when no exercise was performed. Having said that, it has to be taken into account that in respective trial, an amount above the recommended protein intake (1.7 versus 1.2–1.6 g/kg/day^{25,58}) had been prescribed and this amount of 1.7 g/kg/day was furthermore a much higher amount of consumed protein by the non-exercise CG than in FrOST, in which the non-exercise CG only received 1.2 kg/d. Looking at the positive effect of mere supplementation in the FranSO non-exercise CG as opposed to the lack of effect of supplementation in our trial's non-exercise CG raises the question, whether what is considered an adequate protein intake for the elderly, is actually sufficient. We disregard differences in the formula

of the protein powders as a possible reason for this discrepancy because the critical variable Leucine^{26,59–62} was comparably high in both trials. (Levels of Leucine, 9 vs 10.4 g/100 g). Thus, it can be asked whether a protein intake of 1,7-up g/kg/day should be reevaluated with the dosage being the second variable to be considered for explaining this observation. A meta-analysis by Morton et al contradicts additional effects of higher protein consumption than 1,6 g/kg/day,⁶³ and discussions on general effectivity of protein supplementation continue, but there are strong arguments speaking for an increased intake, too.^{58,63–68} Nevertheless, the possible adverse effects of higher protein intake on kidney and colon health cannot be neglected.⁵⁸ Thus, an optimized balance between not too low, but safe enough has to be aimed for. Further investigations are needed to find the maximum dose for certain, specified target groups. However, even with a lower dose of protein than used in the FranSO trial, our training intervention led to a high increase in muscle mass in the HI-RT group, which proves our second hypothesis right – muscle mass significantly increased in the HI-RT&P group, compared to baseline value and the CG.

The change from baseline to FU showed a gain in skeletal body mass of 4.2% at a significance level of < 0.001 , and although we had aimed at such positive results, we did not anticipate this increase because of the blunted hypertrophic potential of skeletal muscles at older age.⁶⁹ Looking at the hypertrophic effect found in our HI-RT group, we speculate that the higher training stimuli outperformed the blunted anabolic system of this older, sarcopenic cohort. This assumption is in line with a recent umbrella review by Beckwée et al stating that more significant improvements in outcomes correlate with higher training intensities.²² The data by Giessing et al²³ about higher muscular performance and mass gain from HI-RT in comparison to traditional high-volume resistance training (HV-RT, ie, high number of repetitions and/or sets and/or frequency^{23,70,71} at low-moderate intensity³³) support our findings as well. Not only exist those advantages of HI-RT but also are there several disadvantages of HV-RT, eg, the longer time of recovery⁷² along with an increased risk of overtraining and a greater inflammatory response⁷² which itself is considered one factor in the genesis of sarcopenia.^{73,74} Additionally, high levels of heart rate and systolic blood pressure have been observed in HV-RT sets,⁷⁵ another factor that plays a role for sarcopenic patients, which often demonstrate cardiovascular comorbidities.⁷⁶ To the best of our knowledge, our study is the first to evaluate the effects of HI-RT in combination with dietary supplementation on sarcopenic community-dwelling

men of such advanced age. Altogether, it was difficult to make valid comparisons to other studies due to heterogeneity in intervention duration, the modality of resistance training, dietary supplements, cohort size, gender, age, definitions applied and missing training protocol. WB-EMS-training interventions^{37,77} with comparable cohorts have also found significant effects on sarcopenia parameters, including the Sarcopenia Z-score. However, the 4.24% increase in SMI was unique to FrOST and outstanding, FranSO achieved an increase in SMI of 2.54%. As listed in the introduction, many adverse health outcomes are correlated with a decrease in muscle mass.^{3–13} On the contrary, positive health outcomes come along with growth of muscle mass. The gain of such is associated with a higher basal metabolic rate^{78,79} helping combat sarcopenic obesity⁸⁰, and an increase in capillary density⁸¹ and Vo2 peak⁸², both improving cardiovascular economy. Furthermore, in recent years, Sarcolipin (SLN) has gained attention, and contrary to previous findings, it has been found to be the leading player in thermogenesis.⁸³ Of importance, this micropeptide is mainly expressed in striated muscle.⁸⁴ SLN ultimately increases ATP hydrolysis and consequently leads to heat production the muscle,⁸⁵ which demands a high level of energy. Thus, next to playing a vital role in non-shivering thermogenesis⁸⁶, it is a determinant of basal metabolic rate.⁸⁷ This is yet another example of the functions of muscle tissue emphasizing on the importance of maintaining and regaining muscle mass.

Apart from muscle mass as one underlying parameter of the Z-score, we also found a significant intergroup effect for handgrip strength, which was maintained in HI-RT, but significantly decreased in GC. Handgrip strength is easy and inexpensive to measure in clinical practice^{88,89} and thus has been put into focus for early detection⁸⁹ and diagnosis of sarcopenia.⁹⁰ More importantly, low handgrip strength has been discovered as a predictive marker for future falls^{91–93} and has also been related to incident cardiovascular disease^{88,94} and cardiovascular mortality⁸⁸ conditions, which are amongst the top 20 causes for disability-adjusted life years (DALYs).⁹⁵ It can be said that it is crucial to maintain muscle strength to combat frailty and mortality, and our intervention sufficed to ensure this. Addressing habitual gait velocity as the last parameter underlying the Z-score, we did not find a significant outcome. Even though gait speed is considered to be a measurand for lower extremity muscle function,⁹⁶ reciprocally, lower extremity muscle function is not the only factor impacting gait speed. Age-related motor neuron degradation,⁹⁷ range of motion in joints of the lower extremities⁹⁸ and non-muscular factors (eg, cognitive

status^{99,100} and depression¹⁰¹) impact gait speed, while muscle mass plays a minor role.⁹⁷ Thus, we do not find it alarming that gait velocity did not increase significantly.

Apart from the strengths of our study, we want to address some limitations in order to help the reader assess our results and the generalizability of our findings: First of all, the time from baseline to FU was 28 weeks with only 8 weeks of a purebred HI-RT (ie, RM⁴¹ in phase 3). During phases 1 and 2, our participants exercised mostly within the suggested range (training intensity between 75% and 80% RM¹⁰²) for novice to moderately trained individuals, as our subjects can be classified. However, work to momentary muscle failure (MF) being the second criterion that defines HI-RT^{23,33} was not introduced during the first three training periods. In our case, trainees chose an intensity of load at 75–85% of their 1RM, which within a defined repetition range, ensured an intensity of effort (sdRM) that almost led to MF. Hence, not all of our protocol followed a high-intensity approach per se. However, we found it absolutely necessary to build good exercise habits first and then prepare the subjects for the demanding phase 3. By applying this strategy, we have successfully managed to avoid injuries. Furthermore, by getting the group slowly used to this unfamiliar training method, we have avoided drop-outs and established a high level of compliance. Although we only applied the strict high-intensity approach in phase 3 for 8 weeks, the outcome was still extraordinarily high. We raise the question of whether we can expect a further significant increase in outcomes from the remaining intervention, now continuously applying the classical HI-RT approach until the end of FrOST? Answers will be given by a later publication, which will be evaluating the endpoint outcomes along with focusing on the outcomes regarding osteopenia.

Secondly, the sample size of this trial might be considered as rather small ($n=21$ and $n=22$). Indeed, the project has been powered on BMD-changes at the LS as determined by QCT. However, a sample size calculation that addresses the Sarcopenia Z-Score provided power at 86% to detect a $p<0.05$ difference using validated assumptions. Thus, we consider the sample size and corresponding statistical power as appropriate in addressing our research topic.

Lastly, we used BIA for measuring the SMI, and there have been the arguments posing an overestimation of SMI by BIA¹⁰³ and consequently suggesting a higher cut-off value of 7.9 kg/m² for males than we did (7.177 kg/m²). We consider the BIA vs DXA discussion irrelevant for the quality of our study for several reasons: 1) In previous studies, Kemmler et al have determined a high interclass correlation between

their DSM-BIA (InBody770) and DXA scanner (Hologic 4500a) for ASMM^{49,104} and Ling et al have found an “excellent agreement” of BIA and DXA.¹⁰⁵ 2) We used BIA for both, baseline and FU, so a possible general overestimation of the SMI would have had no statistical impact. 3) As explained in the methods section of this publication, we used a specifically designed T-score⁴⁹ for our cohort, ensuring the inclusion of only eligible subjects.

Overall, we are delighted with the outcomes of FrOST. We followed a high-quality methodological and statistical approach, showed multiple significant improvements and provided a precise exercise protocol as asked for by reviews, eg, “Exercise interventions in healthy older adults with sarcopenia: A systematic review and meta-analysis” by Vlietstra²¹ to ensure comparability and generalizability.

Conclusion

In conclusion, we summarize that HI-RT in combination with protein supplementation is a favorable intervention strategy to reduce the risks, progression and burden of sarcopenia. The high changes in muscle mass and sarcopenia Z-score can be achieved in an inexpensive, time-efficient and safe manner. The high compliance and lack of injuries in our cohort proved that HI-RT is indeed feasible for the elderly. The present study, along with data from the FranSO-study indicates that there is some evidence, which proposes that protein doses ≥ 1.7 g/kg/day might be required for maintenance of muscle mass without resistance training. Furthermore, studies with a similar exercise protocol changing different variables (eg, trial duration, exercise frequency) should be conducted with more cohorts to have a higher comparable amount of HI-RT trials.

Data Sharing Statement

The authors will neither share the participants’ anonymized data nor other study-related documents.

Acknowledgments

The present work was performed in fulfillment of the requirements for obtaining the degree “Dr. med.”

Disclosure

The authors report no conflicts of interest in this work.

References

- Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. *Age Ageing*. 2010;39(4):412–423. doi:10.1093/ageing/afq034
- Bruyère O, Beaudart C, Locquet M, Buckinx F, Petermans J, Reginster JY. Sarcopenia as a public health problem. *Eur Geriatr Med*. 2016;7(3):272–275. doi:10.1016/j.eurger.2015.12.002
- Scott D, Shore-Lorenti C, McMillan L, et al. Associations of components of sarcopenic obesity with bone health and balance in older adults. *Arch Gerontol Geriatr*. 2018;75:125–131. doi:10.1016/j.archger.2017.12.006
- Balogun S, Winzenberg T, Wills K, et al. Prospective associations of low muscle mass and function with 10-year falls risk, incident fracture and mortality in community-dwelling older adults. *J Nutr Health Aging*. 2017;21(7):843–848. doi:10.1007/s12603-016-0843-6
- Sornay-Rendu E, Duboeuf F, Boutroy S, Chapurlat RD. Muscle mass is associated with incident fracture in postmenopausal women: the OFELY study. *Bone*. 2017;94:108–113. doi:10.1016/j.bone.2016.10.024
- Hars M, Trombetti A. Body composition assessment in the prediction of osteoporotic fractures. *Curr Opin Rheumatol*. 2017;29(4):394–401. doi:10.1097/BOR.0000000000000406
- Kim HT, Kim HJ, Ahn HY, Hong YH. An analysis of age-related loss of skeletal muscle mass and its significance on osteoarthritis in a Korean population. *Korean J Intern Med*. 2016;31(3):585–593. doi:10.3904/kjim.2015.156
- Srikanthan P, Karlamangla AS. Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from the third National Health and Nutrition Examination Survey. *J Clin Endocrinol Metab*. 2011;96(9):2898–2903. doi:10.1210/jc.2011-0435
- Hirasawa Y, Matsuki R, Ebisu T, Kurose T, Hamamoto Y, Seino Y. Evaluation of skeletal muscle mass indices, assessed by bioelectrical impedance, as indicators of insulin resistance in patients with type 2 diabetes. *J Phys Ther Sci*. 2019;31(2):190–194. doi:10.1589/jpts.31.190
- Uematsu M, Akashi YJ, Ashikaga K, et al. Association between heart rate at rest and myocardial perfusion in patients with acute myocardial infarction undergoing cardiac rehabilitation - a pilot study. *Arch Med Sci*. 2012;8(4):622–630. doi:10.5114/aoms.2012.30285
- Gariballa S, Alessa A. Association between muscle function, cognitive state, depression symptoms and quality of life of older people: evidence from clinical practice. *Aging Clin Exp Res*. 2018;30(4):351–357. doi:10.1007/s40520-017-0775-y
- Beaudart C, Biver E, Bruyere O, et al. Quality of life assessment in musculo-skeletal health. *Aging Clin Exp Res*. 2018;30(5):413–418. doi:10.1007/s40520-017-0794-8
- Prado CM, Purcell SA, Alish C, et al. Implications of low muscle mass across the continuum of care: a narrative review. *Ann Med*. 2018;50(8):675–693. doi:10.1080/07853890.2018.1511918
- Dos Santos L, Cyrino ES, Antunes M, Santos DA, Sardinha LB. Sarcopenia and physical independence in older adults: the independent and synergic role of muscle mass and muscle function. *J Cachexia Sarcopenia Muscle*. 2017;8(2):245–250. doi:10.1002/jcsm.v8.2
- Tsekoura M, Kastrinis A, Katsoulaki M, Billis E, Gliatis J. Sarcopenia and its impact on quality of life. *Adv Exp Med Biol*. 2017;987:213–218.
- Beaudart C, Locquet M, Reginster JY, Delandsheere L, Petermans J, Bruyere O. Quality of life in sarcopenia measured with the SarQoL(R): impact of the use of different diagnosis definitions. *Aging Clin Exp Res*. 2018;30(4):307–313. doi:10.1007/s40520-017-0866-9
- Kojima G. Frailty as a predictor of nursing home placement among community-dwelling older adults: a systematic review and meta-analysis. *J Geriatr Phys Ther*. 2018;41(1):42–48. doi:10.1519/JPT.0000000000000097
- Beaudart C, Rizzoli R, Bruyere O, Reginster JY, Biver E. Sarcopenia: burden and challenges for public health. *Arch Public Health*. 2014;72(1):45. doi:10.1186/2049-3258-72-45

19. Bruyere O, Beaudart C, Ethgen O, Reginster JY, Locquet M. The health economics burden of sarcopenia: a systematic review. *Maturitas*. 2019;119:61–69. doi:10.1016/j.maturitas.2018.11.003
20. Liguori I, Russo G, Aran L, et al. Sarcopenia: assessment of disease burden and strategies to improve outcomes. *Clin Interv Aging*. 2018;13:913–927. doi:10.2147/CIA.S149232
21. Vlietstra L, Hendrickx W, Waters DL. Exercise interventions in healthy older adults with sarcopenia: a systematic review and meta-analysis. *Australas J Ageing*. 2018;37(3):169–183. doi:10.1111/ajag.2018.37.issue-3
22. Beckwée D, Delaere A, Aelbrecht S, et al. Exercise interventions for the prevention and treatment of sarcopenia: a systematic umbrella review. *J Nutr Health Aging*. 2019;23:494–502. doi:10.1007/s12603-019-1196-8
23. Giessing J, Eichmann B, Steele J, Fisher J. A comparison of low volume ‘high-intensity-training’ and high volume traditional resistance training methods on muscular performance, body composition, and subjective assessments of training. *Biol Sport*. 2016;33(3):241–249. doi:10.5604/20831862.1201813
24. Law TD, Clark LA, Clark BC. Resistance exercise to prevent and manage sarcopenia and dynapenia. *Annu Rev Gerontol Geriatr*. 2016;36(1):205–228. doi:10.1891/0198-8794.36.205
25. Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. *J Am Med Dir Assoc*. 2013;14(8):542–559. doi:10.1016/j.jamda.2013.05.021
26. Komar B, Schwingshackl L, Hoffmann G. Effects of leucine-rich protein supplements on anthropometric parameter and muscle strength in the elderly: a systematic review and meta-analysis. *J Nutr Health Aging*. 2015;19(4):437–446. doi:10.1007/s12603-014-0559-4
27. Rodrigues I, Armstrong J, Adachi J, Macdermid J. Facilitators and barriers to exercise adherence in patients with osteopenia and osteoporosis: a systematic review. *Osteoporosis Int*. 2016;27:1–11.
28. Rütten A, Abu-Omar K, Meierjürgen R, Lutz A, Adlwarth W. Was bewegt die, Nicht-Beweger? *Prävention und Gesundheitsförderung*. 2009;4:245–250.
29. Shafiee G, Keshkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta-analysis of general population studies. *J Diabetes Metab Disord*. 2017;16:21. doi:10.1186/s40200-017-0302-x
30. Tan LF, Lim ZY, Choe R, Seetharaman S, Merchant R. Screening for frailty and sarcopenia among older persons in medical outpatient clinics and its associations with healthcare burden. *J Am Med Dir Assoc*. 2017;18(7):583–587. doi:10.1016/j.jamda.2017.01.004
31. Gani F, Buettner S, Margonis GA, et al. Sarcopenia predicts costs among patients undergoing major abdominal operations. *Surgery*. 2016;160(5):1162–1171. doi:10.1016/j.surg.2016.05.002
32. Antunes AC, Araujo DA, Verissimo MT, Amaral TF. Sarcopenia and hospitalisation costs in older adults: a cross-sectional study. *Nutr Diet*. 2017;74(1):46–50. doi:10.1111/ndi.2017.74.issue-1
33. Raubold K. *Gesundheitsrelevante Auswirkungen Eines Hochintensiven Muskeltrainings Mit Senioren*. Hamburg: Verlag Dr. Kovač; 2017.
34. Kemmler W, Stengel S, Weineck J, Engelke K. Exercise Recommendations for an Increase of Bone Strength Based on Animal Models and Studies with Athletes. *Deutsche Zeitschrift für Sportmedizin* Vol. 54. 2003.
35. Kemmler W, Von Stengel S. Exercise and osteoporosis-related fractures: perspectives and recommendations of the sports and exercise scientist. *Phys Sportsmed*. 2011;39(1):142–157. doi:10.3810/psm.2011.02.1872
36. Kraemer WJ, Marchitelli L, Gordon SE, et al. Hormonal and growth factor responses to heavy resistance exercise protocols. *J Appl Physiol*. 1990;69(4):1442–1450. doi:10.1152/jappl.1990.69.4.1442
37. Kemmler W, Weissenfels A, Teschler M, et al. Whole-body electromyostimulation and protein supplementation favorably affect sarcopenic obesity in community-dwelling older men at risk: the randomized controlled FranSO study. *Clin Interv Aging*. 2017;12:1503–1513. doi:10.2147/CIA.S137987
38. Kemmler W, von Stengel S, Schoene D. Longitudinal changes in muscle mass and function in older men at increased risk for sarcopenia - The FrOST-Study. *J Frailty Aging*. 2019;8(2):57–61.
39. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. *Am J Epidemiol*. 1998;147(8):755–763. doi:10.1093/oxfordjournals.aje.a009520
40. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. *World Health Organ Tech Rep Ser*. 1994;843(1–129).
41. Steele J, Fisher J, Giessing J, Gentil P. Clarity in reporting terminology and definitions of set endpoints in resistance training. *Muscle Nerve*. 2017;56(3):368–374. doi:10.1002/mus.v56.3
42. Steele J. Intensity; in-ten-si-ty; noun. 1. Often used ambiguously within resistance training. 2. Is it time to drop the term altogether? *Br J Sports Med*. 2014;48(22):1586–1588. doi:10.1136/bjsports-2012-092127
43. Giessing J, Preuss P, Greiwing A, et al. Fundamental definitions of decisive training parameters of single-set training and multiple-set training for muscle hypertrophy. In: Giessing J, Frohlich M, Preuss P, editors. *Current Results of Strength Training Research: An Empirical and Theoretical Approach*. Vol. 1. Goettingen: Cuvillier Verlag; 2005:9–23.
44. Kemmler WK, Lauber D, Wassermann A, Mayhew JL. Predicting maximal strength in trained postmenopausal woman. *J Strength Cond Res*. 2006;20(4):838–842. doi:10.1519/R-18905.1
45. DVO Leitlinie, Osteoporose 2017. Available from: http://www.dv-osteologie.org/dvo_leitlinien/dvo-leitlinie-2017. Published 2017. Accessed January 06, 2019.
46. Chien MY, Huang TY, Wu YT. Prevalence of sarcopenia estimated using a bioelectrical impedance analysis prediction equation in community-dwelling elderly people in Taiwan. *J Am Geriatr Soc*. 2008;56(9):1710–1715. doi:10.1111/j.1532-5415.2008.01854.x
47. Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. *Am J Epidemiol*. 2004;159(4):413–421. doi:10.1093/aje/kwh058
48. Janssen I, Katzmarzyk PT, Ross R. Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines. *Arch Intern Med*. 2002;162(18):2074–2079. doi:10.1001/archinte.162.18.2074
49. Kemmler W, Teschler M, Weissenfels A, Sieber C, Freiburger E, von Stengel S. Prevalence of sarcopenia and sarcopenic obesity in older German men using recognized definitions: high accordance but low overlap! *Osteoporosis Int*. 2017;28(6):1881–1891. doi:10.1007/s00198-017-3964-9
50. Baumgartner RN, Ross R, Heymsfield SB. Does adipose tissue influence bioelectric impedance in obese men and women? *J Appl Physiol* (1985). 1998;84(1):257–262. doi:10.1152/jappl.1998.84.1.257
51. Kressig RW, Beauchet O. Guidelines for clinical applications of spatio-temporal gait analysis in older adults. *Aging Clin Exp Res*. 2006;18(2):174–176. doi:10.1007/BF03327437
52. Peters DM, Fritz SL, Krotish DE. Assessing the reliability and validity of a shorter walk test compared with the 10-meter walk test for measurements of gait speed in healthy, older adults. *J Geriatr Phys Ther*. 2013;36(1):24–30. doi:10.1519/JPT.0b013e318248e20d
53. Mathiowetz V, Weber K, Volland G, Kashman N. Reliability and validity of grip and pinch strength evaluations. *J Hand Surg Am*. 1984;9(2):222–226. doi:10.1016/S0363-5023(84)80146-X

54. Kemmler W, Weineck J, Kalender WA, Engelke K. The effect of habitual physical activity, non-athletic exercise, muscle strength, and VO₂max on bone mineral density is rather low in early postmenopausal osteopenic women. *J Musculoskelet Neuronal Interact*. 2004;4(3):325–334.
55. Honaker J, King G, Blackwell M. Amelia II: a program for missing data. *J Stat Softw*. 2011;45(7):47.
56. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. Hillsdale, N.J.: L. Erlbaum Associates; 1988.
57. Schäfer I, von Leitner E-C, Schön G, et al. Multimorbidity patterns in the elderly: a new approach of disease clustering identifies complex interrelations between chronic conditions. *PLoS One*. 2010;5(12):e15941–e15941. doi:10.1371/journal.pone.0015941
58. Lancha AH Jr, Zanella R Jr, Tanabe SG, Andriamihaja M, Blachier F. Dietary protein supplementation in the elderly for limiting muscle mass loss. *Amino Acids*. 2017;49(1):33–47.
59. Xu ZR, Tan ZJ, Zhang Q, Gui QF, Yang YM. The effectiveness of leucine on muscle protein synthesis, lean body mass and leg lean mass accretion in older people: a systematic review and meta-analysis. *Br J Nutr*. 2015;113(1):25–34. doi:10.1017/S0007114514002475
60. Cheng H, Kong J, Underwood C, et al. Systematic review and meta-analysis of the effect of protein and amino acid supplements in older adults with acute or chronic conditions. *Br J Nutr*. 2018;119(5):527–542. doi:10.1017/S0007114517003816
61. Bauer JM, Verlaan S, Bautmans I, et al. Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study: a randomized, double-blind, placebo-controlled trial. *J Am Med Dir Assoc*. 2015;16(9):740–747. doi:10.1016/j.jamda.2015.05.021
62. Devries MC, McGlory C, Bolster DR, et al. Leucine, not total protein, content of a supplement is the primary determinant of muscle protein anabolic responses in healthy older women. *J Nutr*. 2018;148(7):1088–1095. doi:10.1093/jn/nxy091
63. Morton RW, Murphy KT, McKellar SR, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. *Br J Sports Med*. 2018;52(6):376–384. doi:10.1136/bjsports-2017-097608
64. Thomas DK, Quinn MA, Saunders DH, Greig CA. Protein supplementation does not significantly augment the effects of resistance exercise training in older adults: a systematic review. *J Am Med Dir Assoc*. 2016;17(10):959.e951–959. doi:10.1016/j.jamda.2016.07.002
65. Verreijen AM, Engberink MF, Houston DK, et al. Dietary protein intake is not associated with 5-y change in mid-thigh muscle cross-sectional area by computed tomography in older adults: the Health, Aging, and Body Composition (Health ABC) Study. *Am J Clin Nutr*. 2019;109(3):535–543. doi:10.1093/ajcn/nqy341
66. Rizzoli R, Stevenson JC, Bauer JM, et al. The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). *Maturitas*. 2014;79(1):122–132. doi:10.1016/j.maturitas.2014.07.005
67. Liao CD, Tsauo JY, Wu YT, et al. Effects of protein supplementation combined with resistance exercise on body composition and physical function in older adults: a systematic review and meta-analysis. *Am J Clin Nutr*. 2017;106(4):1078–1091. doi:10.3945/ajcn.116.143594
68. Maltais ML, Ladouceur JP, Dionne IJ. The effect of resistance training and different sources of postexercise protein supplementation on muscle mass and physical capacity in sarcopenic elderly men. *J Strength Cond Res*. 2016;30(6):1680–1687. doi:10.1519/JSC.0000000000001255
69. Csapo R, Alegre LM. Effects of resistance training with moderate vs heavy loads on muscle mass and strength in the elderly: a meta-analysis. *Scand J Med Sci Sports*. 2016;26(9):995–1006. doi:10.1111/sms.2016.26.issue-9
70. MR RHEA, BA ALVAR, LN BURKETT, SD BALL. A meta-analysis to determine the dose response for strength development. *Med Sci Sports Exercise*. 2003;35(3):456–464. doi:10.1249/01.MSS.0000053727.63505.D4
71. TAN B. Manipulating resistance training program variables to optimize maximum strength in men: a review. *J Strength Cond Res*. 1999;13(3):289–304. doi:10.1519/00124278-199908000-00019
72. Bartolomei S. Comparison of the recovery response from high-intensity and high-volume resistance exercise in trained men. *Eur J Appl Physiol*. 2017;117(7):1287–1298. doi:10.1007/s00421-017-3598-9
73. Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. *J Gerontol A Biol Sci Med Sci*. 2002;57(5):M326–M332. doi:10.1093/gerona/57.5.M326
74. Westbury LD, Fuggle NR, Syddall HE, et al. Relationships between markers of inflammation and muscle mass, strength and function: findings from the Hertfordshire Cohort Study. *Calcif Tissue Int*. 2018;102(3):287–295. doi:10.1007/s00223-017-0354-4
75. Lamotte M, Niset G, van de Borne P. The effect of different intensity modalities of resistance training on beat-to-beat blood pressure in cardiac patients. *Eur J Cardiovasc Prev Rehabil*. 2005;12(1):12–17. doi:10.1177/204748730501200103
76. Chin SO, Rhee SY, Chon S, et al. Sarcopenia is independently associated with cardiovascular disease in older Korean adults: the Korea National Health and Nutrition Examination Survey (KNHANES) from 2009. *PLoS One*. 2013;8(3):e60119. doi:10.1371/journal.pone.0060119
77. Kemmler W, Teschler M, Weissenfels A, et al. Effects of whole-body electromyostimulation versus high-intensity resistance exercise on body composition and strength: a randomized controlled study. *Evid Based Complement Alternat Med*. 2016;2016:9236809. doi:10.1155/2016/9236809
78. Curry JJ. Endurance & strength training help reduce fat. *The Times picayune*. 1993;September 1.
79. Holloszy JO. Exercise, health, and aging: a need for more information. *Med Sci Sports Exerc*. 1983;15(1):1–5. doi:10.1249/00005768-198315010-00003
80. Goisser S, Kemmler W, Porzel S, et al. Sarcopenic obesity and complex interventions with nutrition and exercise in community-dwelling older persons—a narrative review. *Clin Interv Aging*. 2015;10:1267–1282. doi:10.2147/CIA.S82454
81. McCall GE, Byrnes WC, Dickinson A, Pattany PM, Fleck SJ. Muscle fiber hypertrophy, hyperplasia, and capillary density in college men after resistance training. *J Appl Physiol* (1985). 1996;81(5):2004–2012. doi:10.1152/jappl.1996.81.5.2004
82. Hepple RT, Mackinnon SL, Goodman JM, Thomas SG, Plyley MJ. Resistance and aerobic training in older men: effects on VO₂peak and the capillary supply to skeletal muscle. *J Appl Physiol* (1985). 1997;82(4):1305–1310. doi:10.1152/jappl.1997.82.4.1305
83. Payne S, Macintosh A, Stock J. Body size and body composition effects on heat loss from the hands during severe cold exposure. *Am J Phys Anthropol*. 2018;166(2):313–322. doi:10.1002/ajpa.v166.2
84. SLN. Available from: https://www.proteinatlas.org/ENSG00000170290-SLN/tissue#gene_information. Accessed July 13, 2019.
85. Sahoo SK, Shaikh SA, Sopariwala DH, Bal NC, Periasamy M. Sarcoplipin protein interaction with sarco(endo)plasmic reticulum Ca²⁺ + ATPase (SERCA) is distinct from phospholamban protein, and only sarcoplipin can promote uncoupling of the SERCA pump. *J Biol Chem*. 2013;288(10):6881–6889. doi:10.1074/jbc.M112.436915

86. Rowland LA, Bal NC, Periasamy M. The role of skeletal-muscle-based thermogenic mechanisms in vertebrate endothermy. *Biol Rev*. 2015;90(4):1279–1297.
87. Maurya SK, Bal NC, Sopariwala DH, et al. Sarcophilin is a key determinant of the basal metabolic rate, and its overexpression enhances energy expenditure and resistance against diet-induced obesity. *J Biol Chem*. 2015;290(17):10840–10849. doi:10.1074/jbc.M115.636878
88. Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. *Lancet (London, England)*. 2015;386(9990):266–273. doi:10.1016/S0140-6736(14)62000-6
89. Ibrahim K, May C, Patel HP, Baxter M, Sayer AA, Roberts H. A feasibility study of implementing grip strength measurement into routine hospital practice (GRImP): study protocol. *Pilot Feasibility Stud*. 2016;2:27. doi:10.1186/s40814-016-0067-x
90. Mijnders DM, Meijers JM, Halfens RJ, et al. Validity and reliability of tools to measure muscle mass, strength, and physical performance in community-dwelling older people: a systematic review. *J Am Med Dir Assoc*. 2013;14(3):170–178. doi:10.1016/j.jamda.2012.10.009
91. Guideline for the prevention of falls in older persons. American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls Prevention. *J Am Geriatr Soc*. 2001;49(5):664–672.
92. Sayer AA, Syddall HE, Martin HJ, Dennison EM, Anderson FH, Cooper C. Falls, sarcopenia, and growth in early life: findings from the Hertfordshire cohort study. *Am J Epidemiol*. 2006;164(7):665–671. doi:10.1093/aje/kwj255
93. Furrer R, van Schoor NM, de Haan A, Lips P, de Jongh RT. Gender-specific associations between physical functioning, bone quality, and fracture risk in older people. *Calcif Tissue Int*. 2014;94(5):522–530.
94. Silventoinen K, Magnusson PK, Tynelius P, Batty GD, Rasmussen F. Association of body size and muscle strength with incidence of coronary heart disease and cerebrovascular diseases: a population-based cohort study of one million Swedish men. *Int J Epidemiol*. 2009;38(1):110–118. doi:10.1093/ije/dyn231
95. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet (London, England)*. 2012;380(9859):2197–2223. doi:10.1016/S0140-6736(12)61689-4
96. Kemmler W, von Stengel S, Kast S, Sieber C, Freiburger E. Longitudinal changes in sarcopenia criteria in older men with low skeletal muscle mass index: a 2-year observational study. *J Sci Sport Exercise*. 2019;1(1):59–68. doi:10.1007/s42978-019-0006-7
97. Clark DJ, Manini TM, Fielding RA, Patten C. Neuromuscular determinants of maximum walking speed in well-functioning older adults. *Exp Gerontol*. 2013;48(3):358–363. doi:10.1016/j.exger.2013.01.010
98. Sakari R, Era P, Rantanen T, Leskinen E, Laukkanen P, Heikkinen E. Mobility performance and its sensory, psychomotor and musculoskeletal determinants from age 75 to age 80. *Aging Clin Exp Res*. 2010;22(1):47–53. doi:10.1007/BF03324815
99. Smith-Ray RL, Hughes SL, Prohaska TR, Little DM, Jurivich DA, Hedeker D. Impact of cognitive training on balance and gait in older adults. *J Gerontol B Psychol Sci Soc Sci*. 2015;70(3):357–366. doi:10.1093/geronb/gbt097
100. Viitasalo JT, Era P, Leskinen AL, Heikkinen E. Muscular strength profiles and anthropometry in random samples of men aged 31–35, 51–55 and 71–75 years. *Ergonomics*. 1985;28(11):1563–1574. doi:10.1080/00140138508963288
101. Lemke MR, Wendorff T, Mieth B, Buhl K, Linnemann M. Spatiotemporal gait patterns during over ground locomotion in major depression compared with healthy controls. *J Psychiatr Res*. 2000;34(4–5):277–283. doi:10.1016/S0022-3956(00)00017-0
102. Wernbom M, Augustsson J, Thomee R. The influence of frequency, intensity, volume and mode of strength training on whole muscle cross-sectional area in humans. *Sports Med*. 2007;37(3):225–264. doi:10.2165/00007256-200737030-00004
103. Fujimoto K, Inage K, Eguchi Y, et al. Use of bioelectrical impedance analysis for the measurement of appendicular skeletal muscle mass/whole fat mass and its relevance in assessing osteoporosis among patients with low back pain: a comparative analysis using dual x-ray absorptiometry. *Asian Spine J*. 2018;12(5):839–845. doi:10.31616/asj.2018.12.5.839
104. Kemmler W, Stengel S, Kohl M. Developing Sarcopenia Criteria and Cutoffs for an Older Caucasian Cohort – A Strictly Biometrical Approach. *Clin Interv Aging* Vol. 13. 2018. doi:10.2147/CIA.S167899
105. Ling CH, de Craen AJ, Slagboom PE, et al. Accuracy of direct segmental multi-frequency bioimpedance analysis in the assessment of total body and segmental body composition in middle-aged adult population. *Clin Nutr*. 2011;30(5):610–615. doi:10.1016/j.clnu.2011.04.001

Clinical Interventions in Aging

Publish your work in this journal

Clinical Interventions in Aging is an international, peer-reviewed journal focusing on evidence-based reports on the value or lack thereof of treatments intended to prevent or delay the onset of maladaptive correlates of aging in human beings. This journal is indexed on PubMed Central, MedLine, CAS, Scopus and the Elsevier

Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-interventions-in-aging-journal>

Dovepress